Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma

Documenti analoghi

• Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non‐Hodgkin lymphoma
  di: Masato Fukae, et al.
  Pubblicazione: (2024)
• An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints
  di: Nathan Braniff, et al.
  Pubblicazione: (2024)
• Automated Poisson regression exposure–response analysis for binary outcomes with PoissonERM
  di: Yuchen Wang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and exposure–safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit
  di: Lu Liu, et al.
  Pubblicazione: (2024)
• Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant
  di: Hee‐yeong Kim, et al.
  Pubblicazione: (2024)